Hidden hepatitis e threat in transplant patients?
NCT ID NCT02190253
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This study checked how many organ transplant recipients in the U.S. have antibodies to the hepatitis E virus, which can become chronic in people with weakened immune systems. Researchers enrolled 447 adults who had a liver, kidney, or small bowel transplant or were on a waiting list. Participants gave a blood sample and answered questions about possible risk factors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study finds that hepatitis E is common in transplant patients, it could lead to better screening and care to prevent chronic infection.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures antibody levels, so it cannot show cause or predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS E are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown University
Washington D.C., District of Columbia, 20007-2197, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104-6056, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.